SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (14540)2/10/1998 7:55:00 PM
From: Torben Noerup Nielsen  Respond to of 32384
 
>Could this just be a case of why spend the money on further trials
>when they will get the same benefit of off-label revenue for Panretin
>and they could better spend the money on other trials?

The KS market is clearly the largets and it is also likely to be the easiest to get approval for. That done, I suspect doctors will be willing to try it for diseases where there are no good alternatives. Looks pretty smart to me. They already know the safety.

Cheers, Torben



To: Arthur Radley who wrote (14540)2/10/1998 11:23:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
TD, I think that the APL trials were having recruiting problems which is why the trials were taking so long. Positive KS results really lays the groundwork for off label use much more effectively.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News